Table 3
Comparison of scabies type, location, and treatment by hospitalization status and scabies classification.
| Outpatient follow-up (n = 1,016) n (%) | Inpatient follow-up (n = 78) n (%) | p * | Classic type (n = 983) n (%) | Crusted type (n = 93) n (%) | Nodular type (n = 18) n (%) | p ** | ||
|---|---|---|---|---|---|---|---|---|
| Scabies type | Classic type | 953 (93.8%) | 30 (38.4%) | <0.001 | 983 (100.0%) | 0 (0%) | 0 (0%) | |
| Crusted type | 55 (5.4%) | 38 (48.7%) | <0.001 | 0 (0%) | 93 (100%) | 0 (0%) | <0.001 | |
| Nodular type | 8 (0.8%) | 10 (12.8%) | <0.001 | 0 (0%) | 0 (0%) | 18 (100%) | ||
| Predominant site of involvement | Head | 58 (5.7%) | 4 (5.1%) | 0.057 | 56 (5.7%) | 5 (5.4 %) | 1 (5.6%) | |
| Trunk | 294 (28.9%) | 13 (16.7%) | 266 (27.0%) | 35 (37.6%) | 6 (33.3%) | 0.241 | ||
| Extremities | 664 (65.4%) | 61 (78.2%) | 661 (67.2%) | 53 (57.0%) | 11 (61.1%) | |||
| Pre-admission treatment | 64 (6.3%) | 11 (14.1%) | 0.009 | 21 (2.1%) | 50 (53.7 %) | 4 (22.2%) | <0.001 | |
| Permethrin | 46 (71.8%) | 7 (63.6%) | 0.440 | 18 (85.7%) | 32 (64.0%) | 3 (75.0%) | ||
| Sulfur-based | 13 (20.3%) | 2 (18.2%) | 0.870 | 2 (9.5%) | 12 (24.0%) | 1 (25.0%) | ||
| Compounded (magistral) | 5 (7.8%) | 2 (18.2%) | 0.272 | 1 (4.8%) | 6 (12.0%) | 0 (0%) | ||
| Treatment prescribed by the pediatrician† | Permethrin | 537 (52.9%) | 43 (55.1%) | 0.689 | 559 (56.9%) | 15 (16.1%) | 6 (33.3%) | <0.001 |
| Sulfur-Based | 334 (32.9%) | 20 (25.6%) | 0.188 | 318 (32.3%) | 28 (30.1%) | 8 (44.4%) | ||
| Compounded (magistral) | 187 (18.4%) | 30 (38.5%) | <0.001 | 175 (17.8%) | 38 (40.9%) | 4 (22.2%) | ||
| Oral ivermectin | 22 (2.2%) | 18 (23.1%) | <0.001 | 0 (0%) | 39 (41.9%) | 1 (5.6%) | ||
| Re-attendance | 120 (11.8%) | 3 (3.8%) | 0.032 | 77 (7.8%) | 44 (47.3%) | 2 (11.1%) | <0.001 | |
*Chi-square (Fisher) Test, **Fisher–Freeman–Halton exact test.
†Some patients received more than one treatment modality; therefore, categories are not mutually exclusive and percentages may exceed 100%.
***Treatment categories refer to documented treatment agents prescribed or recorded in the medical chart. Completion of a second application or dose at Day 7–14/15 and simultaneous treatment of household contacts were not consistently documented; therefore, adherence to the recommended double-treatment schedule could not be tabulated.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.